- Home
- DSGN vs FATE Comparison
DSGN vs FATE Comparison
Compare DSGN & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- FATE
- Stock Information
- Founded
- DSGN 2017
- FATE 2007
- Country
- DSGN United States
- FATE United States
- Employees
- DSGN N/A
- FATE N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DSGN Health Care
- FATE Health Care
- Exchange
- DSGN Nasdaq
- FATE Nasdaq
- Market Cap
- DSGN 208.9M
- FATE 177.7M
- IPO Year
- DSGN 2021
- FATE 2013
- Fundamental
- Price
- DSGN $3.77
- FATE $1.18
- Analyst Decision
- DSGN Hold
- FATE Hold
- Analyst Count
- DSGN 1
- FATE 7
- Target Price
- DSGN $4.00
- FATE $3.83
- AVG Volume (30 Days)
- DSGN 82.2K
- FATE 2.2M
- Earning Date
- DSGN 08-04-2025
- FATE 08-12-2025
- Dividend Yield
- DSGN N/A
- FATE N/A
- EPS Growth
- DSGN N/A
- FATE N/A
- EPS
- DSGN N/A
- FATE N/A
- Revenue
- DSGN N/A
- FATE $13,335,000.00
- Revenue This Year
- DSGN N/A
- FATE N/A
- Revenue Next Year
- DSGN N/A
- FATE N/A
- P/E Ratio
- DSGN N/A
- FATE N/A
- Revenue Growth
- DSGN N/A
- FATE 105.85
- 52 Week Low
- DSGN $2.60
- FATE $0.66
- 52 Week High
- DSGN $7.77
- FATE $5.92
- Technical
- Relative Strength Index (RSI)
- DSGN 49.66
- FATE 44.34
- Support Level
- DSGN $3.33
- FATE $1.02
- Resistance Level
- DSGN $4.21
- FATE $1.22
- Average True Range (ATR)
- DSGN 0.24
- FATE 0.10
- MACD
- DSGN -0.02
- FATE -0.02
- Stochastic Oscillator
- DSGN 50.29
- FATE 26.32
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.